UM  > 健康科學學院
Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
Wei Zheng1; Xiao-Min Zhu2; Qing-E Zhang3; Xin-Hu Yang1; Dong-Bin Cai4; Lu Li1; Xian-Bin Li3; Chee H. Ng5; Gabor S. Ungvari6,7; Yu-Ping Ning1; Yu-Tao Xiang8
2019-04
Source PublicationSchizophrenia Research
ISSN0920-9964
Volume206Pages:13-20
Abstract

Objective: Findings on the efficacy of intranasal oxytocin (IN-OT) in schizophrenia have been inconsistent. This meta-analysis of double-blind randomized controlled trials (RCTs) examined the efficacy and tolerability of adjunctive IN-OT in the treatment of schizophrenia.

Methods: Standardized mean differences or risk ratios (SMDs or RRs) with their 95% confidence intervals (CIs) were used to synthesize the results of studies included in the meta-analysis.

Results: Ten RCTs (n = 344) with 172 schizophrenia subjects on adjunctive IN-OT [range = 40-80 International Units (IU)/day] and 172 schizophrenia subjects on adjunctive placebo over 2-16 weeks were included. No significant differences regarding total psychopathology measured with the total Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS) [8 RCTs, n = 203; SMD: -0.08 (95% CI: -0.53, 0.37), P = 0.74, I-2 = 59%] and the positive, negative and general symptom scores [SMD: -0.20 to -0.04 (95% CI: -0.75, 0.36), P = 0.28 to 0.78; I-2 = 0% to 72%] were found between the IN-OT and placebo groups. Similarly, subgroup analyses for total psychopathology found no group differences. Dose-response effect analyses showed that only 80 IU/day IN-OT had superiority over placebo in improving total psychopathology (P = 0.02) and positive symptom score (P = 0.01). No group differences between adjunctive IN-OT and placebo regarding discontinuation due to any reason [RR: 1.12 (95% CI: 0.67, 1.88), P = 0.67, I-2 = 0%] and adverse drug reactions were found.

Conclusions: Although the meta-analysis did not show a positive effect in general, the higher dose of adjunctive IN-OT (80 IU/day) appears to be efficacious and safe in improving total psychopathology and positive symptoms in schizophrenia.

KeywordOxytocin Schizophrenia Augmentation Meta-analysis
DOI10.1016/j.schres.2018.12.007
Indexed BySSCI
Language英语
WOS Research AreaPsychiatry
WOS SubjectPsychiatry
WOS IDWOS:000467810100004
Fulltext Access
Citation statistics
Cited Times [WOS]:4   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorYu-Ping Ning; Yu-Tao Xiang
Affiliation1.The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
2.Suzhou Psychiatric Hospital, The Affiliated Guangji Hospital of Soochow University, Suzhou, China
3.The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders Beijing Anding Hospital & the Advanced Innovation Center for Human Brain Protection, Capital Medical University, School of Mental Health, Beijing, China
4.Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China
5.Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
6.The University of Notre Dame Australia, Fremantle, Australia
7.Division of Psychiatry, Medical School, University of Western Australia, Perth, Australia
8.Unit of Psychiatry, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China
Corresponding Author AffilicationFaculty of Health Sciences
Recommended Citation
GB/T 7714
Wei Zheng,Xiao-Min Zhu,Qing-E Zhang,et al. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials[J]. Schizophrenia Research,2019,206:13-20.
APA Wei Zheng.,Xiao-Min Zhu.,Qing-E Zhang.,Xin-Hu Yang.,Dong-Bin Cai.,...&Yu-Tao Xiang.(2019).Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.Schizophrenia Research,206,13-20.
MLA Wei Zheng,et al."Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials".Schizophrenia Research 206(2019):13-20.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wei Zheng]'s Articles
[Xiao-Min Zhu]'s Articles
[Qing-E Zhang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wei Zheng]'s Articles
[Xiao-Min Zhu]'s Articles
[Qing-E Zhang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wei Zheng]'s Articles
[Xiao-Min Zhu]'s Articles
[Qing-E Zhang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.